European Journal of Cardiovascular Medicine

Heart failure remains a significant cause of global morbidity and mortality. The identification of accurate prognostic markers can be pivotal in patient management. Galectin-3 (Gal-3), a biomarker, has recently been studied for its potential in assessing heart failure prognosis.A comprehensive assessment of heart failure patients was conducted, focusing on demographics, clinical features, and biomarker evaluations. Galectin-3 levels were central to this analysis. Advanced statistical tools, including Pearson’s correlation and ROC analysis, were employed to analyze the data. A marked variability was observed in Galectin-3 levels based on clinical parameters. Notably, patients with three chambers dilated presented the highest average Gal-3 levels at 109.67 ± 96.111. The mean distribution of Galectin-3 levels on patients who died was 106.3 compared to patients who were alive was 55.46. The mean distribution of Galectin-3 levels of patients who were intubated was 84.04 as compared to non intubated patients , were 57.03. The mean galectin 3 levels in stage 3 of breathlessness was 61.06 ± 44.35  and in stage 4 of breathlessness was 82.73 ± 56.57 correlating the severity of breathlessness with high Galectin levels.Galectin-3 stands out as a crucial prognostic biomarker in heart failure patients, offering valuable insights into patient management and potential outcomes. death. In patients with deteriorating HF, measuring galectin-3 could be a key component in prognostic utility for in hospital mortality.